Pharmacy
News
FDA approves new formulation of mercaptopurine
Credit: Bill Branson The US Food and Drug Administration (FDA) has approved an oral suspension of mercaptopurine (Purixan), a drug used in...
News
FDA approves first drug for multicentric Castleman’s disease
Credit: Janssen Biotech, Inc. The US Food and Drug Administration (FDA) has authorized marketing of siltuximab (Sylvant), the first drug approved...
News
Bortezomib available for newly diagnosed MM patients
Credit: CDC Patients with newly diagnosed multiple myeloma (MM) will now be guaranteed access to bortezomib (Velcade) through the National Health...
News
Drug gets orphan designation for AML
Credit: NIH The US Food and Drug Administration and the European Commission have granted volasertib orphan designation for the treatment of acute...
News
FDA approves ofatumumab in combination for CLL
Credit: Linda Bartlett The US Food and Drug Administration (FDA) has approved ofatumumab (Arzerra) in combination with chlorambucil for...
News
FDA approves new indications for dabigatran
Credit: Andre E.X.
Conference Coverage
Enrollment stalled for CAR T-cell study
Memorial Sloan-Kettering Cancer Center has temporarily suspended enrollment in a study of chimeric antigen receptor (CAR) T-cell therapy, due to 2...
News
Pharmacogenomic studies follow 90/10 rule
Credit: NIGMS Few pharmacogenomic studies focus on orphan or tropical diseases prevalent in developing countries, according to research published...
News
Product gets orphan designation for AML
The US Food and Drug Administration (FDA) has granted orphan designation for eryaspase to treat acute myeloid leukemia (AML). Eryaspase, also...
News
FDA working to alleviate saline shortage
In an attempt to alleviate the shortage of saline (0.9% sodium chloride injection) in the US, the Food and Drug Administration (FDA) is allowing...
News
EC approves SC formulation of rituximab
The European Commission (EC) has approved a subcutaneous (SC) formulation of rituximab (MabThera) to treat patients with follicular lymphoma or...